Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity

Document first published:
Page updated:
Topic:
,
Publication type:

This interim commissioning guidance outlines NHS England’s approach to implementing tirzepatide (Mounjaro®) into the weight management pathway. The full guidance will be issued after an evaluation by NICE of the initial 3-year rollout.

Link

Interim commissioning guidance: tirzepatide (Mounjaro®)

Interim commissioning guidance: tirzepatide (Mounjaro®)

NHS England is not responsible for content on external websites.

Summary

Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity

Accessible content. Published 2 April 2026.